Ignite Creation Date:
2024-05-06 @ 5:20 PM
Last Modification Date:
2024-10-26 @ 2:26 PM
Study NCT ID:
NCT05271318
Status:
RECRUITING
Last Update Posted:
2024-05-23
First Post:
2022-02-04
Brief Title:
Oncolytic Adenovirus Coding for TNFa and IL2 TILT-123 With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer
Sponsor:
TILT Biotherapeutics Ltd
Organization:
TILT Biotherapeutics Ltd
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-05-17
Start Date Type:
ACTUAL
Primary Completion Date:
2025-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-01
Completion Date Type:
ESTIMATED
First Submit Date:
2022-02-04
First Submit QC Date:
March 2 2022
Study First Post Date:
2022-03-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-21
Last Update Post Date:
2024-05-23
Last Update Post Date Type:
ACTUAL